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Abstract—Heart failure is the leading cause of death in the elderly, but whether this is the result of a primary aging
myopathy dictated by depletion of the cardiac progenitor cell (CPC) pool is unknown. Similarly, whether current
lifespan reflects the ineluctable genetic clock or heart failure interferes with the genetically determined fate of the organ
and organism is an important question. We have identified that chronological age leads to telomeric shortening in CPCs,
which by necessity generate a differentiated progeny that rapidly acquires the senescent phenotype conditioning organ aging.
CPC aging is mediated by attenuation of the insulin-like growth factor-1/insulin-like growth factor-1 receptor and hepatocyte
growth factor/c-Met systems, which do not counteract any longer the CPC renin–angiotensin system, resulting in cellular
senescence, growth arrest, and apoptosis. However, pulse-chase 5-bromodeoxyuridine–labeling assay revealed that the
senescent heart contains functionally competent CPCs that have the properties of stem cells. This subset of telomerase-
competent CPCs have long telomeres and, following activation, migrate to the regions of damage, where they generate a
population of young cardiomyocytes, reversing partly the aging myopathy. The senescent heart phenotype and heart failure
are corrected to some extent, leading to prolongation of maximum lifespan. (Circ Res. 2008;102:597-606.)
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Heart failure is the leading cause of death in the elderly,but whether this is the result of a primary aging
myopathy or the consequence of coronary artery disease is
unknown. In humans, it is difficult to separate the inevitable
pathology of the coronary circulation with age from the
intrinsic mechanisms of myocardial aging and heart failure.
The aging heart typically shows a decreased functional
reserve and limited capacity to adapt to cardiac diseases.
Although the old heart cannot accommodate sudden increases
in pressure and volume loads,1 the critical question is whether
the etiology of ventricular decompensation in the elderly is
the product of aging-associated events or the result of primary
aging effects on the pool and function of cardiac progenitor
cells (CPCs). A related question is whether average lifespan
reflects the ineluctable genetic clock2 or whether heart failure
interferes with the programmed death of the organ and
organism, negatively affecting lifespan.
With the exception of a few hematological disorders,3 stem
cell failure does not occur in self-renewing organs, including the
human heart. Functionally competent CPCs are present in the
hearts of patients who die acutely after a large myocardial infarct
or undergo cardiac transplantation for end-stage ischemic car-
diomyopathy.4 Similarly, cycling CPCs with long telomeres
have been identified in the old decompensated human heart.5
Functional CPCs may not sense signals from the regions of
damage, or their activation, growth, and migration may be
impaired, and these variables interfere with the ability of resident
CPCs to repair the old heart and preserve its youth. These issues
have been addressed in the current study, in which an animal
model of normal aging has been used to determine the role that
CPCs have in physiological aging and establish whether chro-
nological age impacts on the number and properties of CPCs.
Additionally, we tested whether myocardial aging can be re-
versed by repopulating the senescent heart with new myocytes
derived from differentiation of locally activated CPCs. Ulti-
mately, the profound restructuring of the old heart was expected
to prolong animal lifespan.
Materials and Methods
Male Fischer rats (Harlan, Indianapolis, Ind) of different ages were
characterized physiologically, structurally, and biochemically. Sub-
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sequently, animals were injected intramyocardially with hepatocyte
growth factor (HGF) and insulin-like growth factor (IGF)-1 to establish
the effects of this intervention on myocardial regeneration, organ aging,
and animal lifespan. Experimental protocols are described in the online
data supplement, available at http://circres.ahajournals.org.
Results
CPC Aging and Death
To define whether myocardial aging is conditioned by alter-
ations in CPC function, we measured the number of CPCs
together with the expression of the aging-associated protein
p16INK4a6 in male rats at 4, 12, 20, and 28 months. CPCs are
lineage-negative (Linneg) cells that express the stem cell
antigens c-kit, MDR-1, and Sca-1, alone or in combination.7
Linneg CPCs are clustered in cardiac niches,8 which are
located predominantly in the atria and apex. This study is
mostly restricted to c-kit–positive CPCs because of their
superior growth and differentiation behavior.9
From 4 to 28 months, CPCs increased 2.9-fold and
p16INK4a-positive CPCs 12-fold. Similarly, apoptosis in-
creased with age and was restricted to p16INK4a-positive CPCs.
As a result, the number of functionally competent CPCs
remained constant up to 20 months and decreased sharply at
28 months (Figure I in the online data supplement).
CPC Activation and Differentiation
The aging myopathy is characterized by an increased myocyte
mitotic index5 that reflects CPC activation and lineage commit-
ment.10 Myocyte progenitors/precursors correspond to differen-
tiating CPCs that express c-kit and transcription factors and
cytoplasmic proteins specific to myocytes. This documents the
linear relationship between CPCs and forming myocytes. CPCs
positive for the myocyte transcription factor MEF2C, ie, myo-
cyte progenitors, or both MEF2C and the sarcomeric protein
cardiac myosin heavy chain (MHC), ie, myocyte precur-
sors, increased with age (supplemental Figure I).
Pulse-chase 5-bromodeoxyuridine (BrdUrd)-labeling assay
was performed8 because this protocol, together with the identi-
fication of c-kit, allowed us to assess whether the senescent heart
contained functionally competent CPCs with the properties of
stem cells.11 Rats at 4 and 27 months were exposed to BrdUrd
for 7 days, and BrdUrd-positive CPCs were measured at 7 days
and after 12 weeks of chasing. Bright and dim BrdUrd-labeled
CPCs were discerned by fluorescence intensity to score long-
term label-retaining CPCs; this provides a functional identifica-
tion of resident stem cells.11
Recently, the long-term BrdUrd-retaining assay was chal-
lenged. The argument was made that isolation of hematopoietic
stem cells (HSCs) by fluorescence-activated cell sorting is
superior in specificity and sensitivity to the analysis of stem cells
at the single-cell level within tissues.12 Unfortunately, the inten-
sity of BrdUrd fluorescence after chasing was not evaluated.
Instead, the number of cells with “detectable” BrdUrd levels was
measured. Arbitrarily, the threshold of BrdUrd labeling was set
at 6% of the signal of BrdUrd-positive cells at the end of the
pulse period; the protocol was arranged to identify BrdUrd-
positive cells not to distinguish the distribution of BrdUrd levels
in HSCs. It is unrealistic that all examined HSCs experienced the
same number of divisions and had identical levels of BrdUrd
incorporation. By design, preservation of the BrdUrd signal or
its dilution with time was not determined, defeating the purpose
of the BrdUrd-retaining assay.
In the current study, after 12 weeks of chasing, the number
of BrdUrd-bright CPCs detected at 7 days decreased 86% and
93% in young and old animals, respectively. At 7 days, 532
and 2012 BrdUrd-bright CPCs were found in young and old
hearts, respectively. Corresponding values at 12 weeks were
73 and 140; they constituted slow-cycling stem cells (Figure
1A and 1B). From 7 days to 12 weeks, BrdUrd-dim CPCs
increased 10-fold in young and 32-fold in old hearts. The
number of BrdUrd-bright and BrdUrd-dim CPCs did not
change in 12 weeks in young but increased in old animals.
Thus, the growth kinetics of CPCs preserves the pool of
primitive cells in the young heart but expands this compartment
in the old myocardium. The number of BrdUrd-bright CPCs in
other self-renewing organs, including the skin and ocular bulb, is
several orders of magnitude higher than in the heart.13,14 How-
ever, the heart and bone marrow15 have similar values.
BrdUrd-positive myocytes were measured at 7 days (sup-
plemental Figure IIA) and 12 weeks. BrdUrd-bright myocytes
at 12 weeks were cells that experienced a limited number of
divisions, whereas BrdUrd-dim myocytes were considered
the progeny of CPCs, which became BrdUrd-positive at the
time of exposure and formed a large number of committed
cells. Cells with intermediate BrdUrd levels were assumed to
represent amplifying myocytes that incorporated BrdUrd at
the time of exposure and continued to divide and differenti-
ate. Scattered BrdUrd-positive myocytes were observed at 7
days. Following chasing, clusters of BrdUrd-dim myocytes
together with BrdUrd-bright myocytes were detected pre-
dominantly in old animals. The percentage of BrdUrd-
positive myocytes was 5.3-fold higher in old than in young
hearts (Figure 1C and 1D). In both cases, the number of
BrdUrd-bright myocytes decreased markedly with chasing,
whereas BrdUrd-dim myocytes increased.
The high level of myocyte formation in old hearts was
confirmed by the myocyte mitotic index measured in situ and
in isolated cells (Figure 1E and 1F and supplemental Figure
II). It is remarkable that 45% of myocytes were replaced in
12 weeks in senescent animals; this value was 5-fold larger
than in young rats. However, in spite of this dramatic increase
in new myocytes, cell death exceeds myocyte regeneration
and the aging myopathy cannot be prevented.5,16 Addition-
ally, the increased number of cycling cells in the senescent
heart is consistent with the enhanced toxicity of anticancer
drugs in the elderly.17
CPC and Myocyte Senescence
The accumulation of p16INK4a-positive myocytes with age16 may
be mediated by differentiation of CPCs with short telomeres,
which form a myocyte progeny that rapidly reaches cellular
senescence. Therefore, telomere length was measured in c-kit–
positive cells (Figure 2A through 2C) and developing myocytes
expressing the cell cycle protein Ki67 (supplemental Figure III).
Telomere length in CPCs, myocyte progenitors/precursors and
developing myocytes was 30%, 35%, and 51% shorter in old
than young cells, respectively (Figure 2D); 50% of old and
15% of young CPCs had telomeres less than 12 kbp and were
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p16INK4a-positive. However, 20% of old CPCs had telomeres
18 kbp, pointing to a relevant growth reserve of the senescent
myocardium. Thus, telomere attrition in CPCs with age leads to
the generation of a myocyte progeny that acquires quickly the
senescent phenotype conditioning organ aging.
CPC Aging and Growth Factor Receptor Systems
The IGF-1/IGF-1R pathway preserves telomere length and
promotes CPC growth and survival,16 whereas CPC migra-
tion and homing are predominantly modulated by the HGF/
c-Met receptor system.9 Although the consequences of angio-
tensin (Ang) II on CPCs are unknown, this growth factor
decreases the number and function of endothelial progenitor
cells, triggers apoptosis, and is implicated in the progression
of heart failure.18 Therefore, we determined whether aging
alters IGF-1/IGF-1R and HGF/c-Met in CPCs and whether
CPCs possess a local renin–angiotensin system (RAS), which
is influenced by age.
CPCs express IGF-1R, c-Met, and Ang II type 1 (AT1)
receptors, together with IGF-1, HGF, and Ang II (supplemen-
tal Figure IV). Detection of Ang II, IGF-1, and HGF in
freshly isolated CPCs and tissue sections cannot discriminate
whether growth factors are formed within cells or sequestered
from the circulation. However, transcripts for renin, angio-
tensinogen (Aogen), and AT1 receptor were detected by
real-time RT-PCR in CPCs isolated from hearts at 3, 12, 16,
and 24 months (Figure 3A and supplemental Figure V). CPC
aging resulted in downregulation of Aogen and AT1 recep-
tors, whereas renin mRNA increased at 12 and 16 months,
returning to baseline at 24 months. Although changes in
mRNAs occurred with age, the protein levels of Aogen and
AT1 receptors did not vary (Figure 3B), suggesting that RAS
function remained intact in old CPCs.
The CPC IGF-1/IGF-1R system was characterized by a
significant decrease in IGF-1R mRNA with aging, whereas
IGF-1 expression was variable and tended to be reduced only
at 24 months. c-Met transcripts were modestly affected in
aging CPCs, but HGF mRNA was attenuated at 24 months
(Figure 3C and supplemental Figure V).
Figure 1. CPC aging and growth. A, Old heart after 12 weeks of chasing: atrial niche in which 1 CPC is BrdUrd-bright (magenta; arrow)
and 7 are BrdUrd-dim (arrowheads). The BrdUrd-bright CPCs is Linneg (GATA-4-negative). One BrdUrd-dim myocyte is visible
(-sarcomeric actin, -SA, asterisk). B, BrdUrd-bright and -dim CPCs at 7 days and 12 weeks. C, Old LV: BrdUrd (yellow) -bright
(arrows), -intermediate (open arrowheads), and -dim (arrowheads) myocytes at 12 weeks. D, BrdUrd-bright, -intermediate, and -dim
myocytes at 7 days and 12 weeks. *P0.05 vs 7 days (7d); **P0.05 vs young hearts. E, Metaphase and anaphase chromosomes in
dividing myocytes from young (top) and old (bottom) hearts. Phospho-H3, green. F, Myocyte mitotic index. *P0.05 vs young hearts.
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The ability of CPCs to synthesize IGF-1, HGF, and Ang II
was measured. Baseline values for IGF-1 were similar in
young and old CPCs, but HGF tended to be lower in old cells.
Ang II levels, however, were 3-fold higher in old than in
young CPCs (Figure 3D). Following ligand stimulation,
IGF-1 formation was 8-fold higher in cells at 3 than at 27
months, whereas HGF synthesis increased 4-fold in young
and 3.5-fold in old CPCs. Ang II stimulation did not increase
octapeptide synthesis in either cell population. Thus, aging
negatively affects regulatory systems involved in CPC
growth, survival, and migration, potentiating the detrimental
consequences of the local RAS.
CPC Division and Apoptosis
CPCs were cultured in serum-free medium and stimulated
with Ang II, IGF-1, HGF, or IGF-1 and HGF together
(IGF-1/HGF). The ability of IGF-1, HGF, and IGF-1/HGF to
induce CPC proliferation was attenuated but not abolished in old
CPCs. Ang II had no growth-promoting effects on CPCs (Figure
4A). Ang II stimulated CPC apoptosis, and IGF-1 decreased the
extent of Ang II–mediated CPC death. Conversely, HGF did not
decrease apoptosis or enhanced the effects of IGF-1 on CPC
survival. Although the inhibitory role of IGF-1 in CPC apoptosis
was higher in young than in old cells, a 40% reduction in
apoptosis was measured in old CPCs.
A question concerned the impact of Ang II on young and old
CPCs because the rate of apoptosis triggered by Ang II was
comparable in the 2 cell populations. Ang II leads to the
generation of hydroxyl radical, which promotes deoxyguanosine
(dG) oxidation, a process that may vary in young and old CPCs.
In the presence of hydroxyl radical, the formation of 8-OH-dG
lesions is 5-fold higher in telomeric than in nontelomeric
DNA.19 Importantly, 8-OH-dG was detected in a larger fraction
of old than young CPCs (Figure 4B through 4D) and Ang II
further enhanced this phenomenon, providing a mechanism for
Ang II–mediated DNA damage with age.
Aging, CPC Heterogeneity, and Growth
We then established whether these growth factor receptor
systems were uniformly affected in aging CPCs or aging
progressively involved a larger number of CPCs leaving
intact a subset of progenitor cells. The fraction of CPCs
positive for IGF-1, IGF-1R, HGF, and c-Met decreased from
3 to 28 months, and the percentage of CPCs expressing Ang
II and AT1 receptors increased (Figure 5A). CPCs expressing
IGF-1/IGF-1R and HGF/c-Met were consistently negative for
p16INK4a, whereas p16INK4a was detected in CPCs positive for
Ang II and AT1 receptors.
To test whether a small proportion of old CPCs possessed
a growth potential similar to young CPCs, CPCs at 3 and 27
Figure 2. CPCs and telomere length. Telomeres (magenta) in isolated CPCs from
young (A) and old (B) hearts. Linneg CPCs (c-kit, green; arrows), myocyte progenitors
(Nkx2.5, white; arrowheads) and myocyte precursors (-SA, red; asterisks) are pres-
ent. C, Lymphoma cells with long (L5178Y-R, 48 kbp) and short (L5178Y-S, 7 kbp)
telomeres. D, Telomeric length in Linneg CPCs, myocyte progenitors/precursors and
amplifying myocytes in young (top graphs) and old (bottom graphs) hearts. Average
telomere length is listed together with the percentage of cells with telomeres 12
kbp and 18 kbp. Fractions of cycling cells (green solid bars) and senescent
p16INK4a-positive cells (red solid bars) are shown.
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Figure 3. CPCs and growth factor receptor systems.
A, Renin, Aogen, and AT1 receptor mRNAs in CPCs
as a function of age. Fold changes in mRNAs are
shown with respect to young CPCs at 3 months. B,
Protein levels of Aogen and AT1 receptors in young
(3-month) and old (27-month) CPCs. Lung (L) and
kidney (K) tissue lysates were used as positive con-
trols. C, IGF-1R, IGF-1, c-Met, and HGF mRNAs in
CPCs as a function of age. D, Formation of IGF-1,
HGF, and Ang II in nonstimulated and ligand-
stimulated CPCs for 24 hours. Values were normal-
ized by total amount of CPC protein and -actin
expression. *P0.05 vs 3 months (3m), **P0.05 vs
nonstimulated CPCs.
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months were serially passaged to reach 20 population dou-
blings. Although the lag-growth phase was longer in old
CPCs, the exponential-growth phase was similar in both cell
classes (Figure 5B). Similarly, BrdUrd labeling at passage P7
to P8 resulted in comparable levels of BrdUrd-positive CPCs,
and telomerase activity in old CPCs decreased only 33%
(Figure 5C). Thus, myocardial aging does not deplete the
pool of functionally competent CPCs.
CPC Aging and Cell Mobilization
The presence of a compartment of nonsenescent CPCs in the
aged heart raised the possibility that these cells may be activated
and induced to translocate from their sites of storage in the atria
and apex to the base/midregion of the left ventricle (LV). A
retroviral vector encoding enhanced green fluorescent protein
(EGFP) was injected into the atrioventricular groove to label
replicating cells in animals at 4 and 27 months (supplemental
Figure VI). A retrovirus was used to infect only replicating cells
and avoid cell cycle activation in terminally differentiated
myocytes. In both cases,9% to 12% c-kit–positive CPCs were
infected with EGFP; this value was consistent with the fraction
of Ki67-positive CPCs in this region (data not shown). Two days
later, 3 increasing concentrations of HGF were administered
Figure 4. CPCs and IGF-I, HGF, and
Ang II. A, Proliferation and apoptosis of
young and old CPCs. Percentage
changes were computed with respect to
nonstimulated CPCs. *P0.05 vs 3
months (3m). Localization of 8-OH-dG
(magenta) in young (B) and old (C) CPCs
at baseline (left images) and following
Ang II stimulation (right images). D,
CPCs positive for 8-OH-dG. *P0.05 vs
3 months; †P0.05 vs serum-free
medium.
Figure 5. CPC characteristics. A, CPCs
positive for IGF-1, IGF-1R, HGF, c-Met,
Ang II, and AT1 receptors. *P0.05 vs 4
months and 12 months, **P0.05 vs 20
months. B, Population doubling time and
BrdUrd labeling of CPCs from young
(3-month) and old (27-month) hearts. C,
Telomerase activity in young (3-month)
and old (27-month) CPCs. Telomerase
activity starts at 50 bp and displays 6 bp
periodicity. HeLa cells were used as pos-
itive control, and samples treated with
RNase were used as negative control.
TSR8 was used to confirm the position of
the bands. Three protein concentrations
were used to validate the specificity of
the assay. The band at 36 bp is an inter-
nal control for PCR efficiency.
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from the site of CPC accumulation in proximity of the atrioven-
tricular groove to the LV midregion (supplemental Figure VI).
The migration of EGFP-positive cells was then determined by
2-photon microscopy (supplemental Figures VII through X).
The myocardial area examined by 2-photon microscopy
was analyzed subsequently by confocal microscopy to char-
acterize the identity of the migrated EGFP-positive cells.
Translocated EGFP-positive cells expressed c-kit, MDR1, or
Sca-1 together with c-Met. Moreover, GATA-4 was detected
in some cells, documenting their commitment to the myocyte
lineage. Ki67 was present in a subset of EGFP-positive cells
(supplemental Figures VIII and X).
To determine whether translocation of EGFP-positive cells
occurred through the coronary circulation, myocardial intersti-
tium, or both, the coronary vasculature was perfused with
rhodamine-labeled dextran, and HGF was injected at the time of
observation. Over 5 to 6 hours, none of the moving EGFP-
positive cells was found within the lumen of coronary vessels
(Figure 6A and supplemental Figure XI); CPCs migrated
through the interstitium within tunnels defined by fibronectin.
HGF mobilized and translocated CPCs from the atrioventric-
ular groove toward the LV midregion. Two aging effects were
observed: the speed of migration and the number of migrating
CPCs were significantly higher in young than in old hearts
(supplemental Figure XII). Because of the growth-promoting
effects of IGF-1 on CPCs,9 IGF-1 was injected alone or in
combination with HGF, and the number and rate of migration of
EGFP-positive cells was determined together with the fraction of
cycling EGFP-positive cells. In young and old hearts, IGF-1
failed to stimulate the locomotion of CPCs and to increase the
migratory ability of HGF. However, IGF-1 significantly in-
creased the number of dividing CPCs in both young and old
hearts (supplemental Figure XII).
Migrating CPCs and their early committed progeny had
long telomeres and were p16INK4a-negative. This was in
contrast to the properties of nontranslocated CPCs in the LV
midregion of control hearts. These cells had short telomeres
and frequently expressed p16INK4a (supplemental Figure XII).
These results suggest that functionally competent CPCs were
stored in atrial niches, whereas aging effects were more
prominent in the midregion of the LV myocardium.
CPC Aging and Myocardial Regeneration
To test whether the negative effects of aging on the heart
could be reversed by activation of resident CPCs, HGF and
Figure 6. CPC migration and myocardial regeneration. A, Rat heart
at 27 months. Colored arrowheads point to EGFP-positive cells
(green) moving in the direction of the yellow open arrows. Coronary
vasculature (rhodamine-labeled dextran, red). Newly formed EGFP-
positive cardiomyocytes (EGFP, green; MHC, red; arrows) (B and C)
in 28- to 29-month hearts treated with growth factors. Area of myo-
cardial regeneration. EGFP, green (D); MHC, red (E); BrdUrd, white
(F). G, Merge of D, E, and F.
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IGF-1 were injected intramyocardially into rats at 15, 20, and
27 months of age (supplemental Figure XIII). The animals
were euthanized 45 days later. Two days before growth factor
administration, the atrioventricular groove and the apex were
injected with the EGFP–retrovirus to label cycling CPCs.
In all treated rats, EGFP-positive myocytes, coronary
arterioles, and capillaries were identified in the LV midregion
(Figure 6B and 6C and supplemental Figure XIV). Con-
versely, EGFP-positive myocytes and vessels were absent in
untreated animals. Frequently, clusters of regenerated myo-
cytes replaced foci of myocardial damage (Figure 6D through
6G). Quantitatively, the number of EGFP-positive myocytes
was significantly higher in rats at 28 to 29 months than at 16
to 17 and 21 to 22 months. A similar response was observed
for coronary vessels (supplemental Figure XIV).
EGFP-labeled structures reflected only partly the extent of
tissue regeneration because9% to 12% CPCs were infected
by the EGFP–retrovirus. Thus, BrdUrd was given after the
delivery of growth factors or vehicle and was continued
throughout to assess cumulative myocyte and vessel forma-
tion. Without treatment, myocyte and vessel growth increased
with age, pointing to the ability of the old heart to react to
tissue injury. Growth factor administration increased cardio-
myocyte formation by 55%, 66%, and 88% at 16 to 17, 21 to
22, and 28 to 29 months, respectively (Figure 7A). Vessel
regeneration also occurred (supplemental Figure XV). In
treated hearts at 28 to 29 months, new myocytes decreased by
20% the number of p16INK4a-positive cells (Figure 7B), and
this change reflected the increase in BrdUrd-labeled cells.
Remodeling of the Aging Heart and Mortality
Myocardial regeneration mediated by CPC activation atten-
uated ventricular dilation and the decrease in ventricular
mass-to-chamber volume ratio (supplemental Figure XVI),
resulting in improvement of cardiac function in animals at 28
to 29 months. Without treatment, heart failure at 27 months
deteriorated further at 28 to 29 months. Following treatment,
the alterations in ventricular pressures, dP/dt, and diastolic
stress at 27 months were no longer apparent at 28 to 29
months (Figure 7C). The anatomy and function of treated
hearts at 28 to 29 months became similar to the anatomy and
function of untreated hearts at 16 to 17 months (Figure 8A).
Echocardiography was performed in rats at 27 months, 1
day before treatment, and 45 days later, before euthanasia, at
28 to 29 months. Therapy significantly decreased end-dia-
stolic and end-systolic LV diameters, whereas ejection frac-
tion increased 12 percentage points, from 677% to 797%.
The improvement in cardiac function was apparent when
early and late echocardiograms were compared (supplemental
Figure XVII and Movies I and II). In untreated rats, ventric-
ular hemodynamics deteriorated with time (Figure 8B).
A mortality study was conducted in a cohort of 32
untreated and 48 treated rats at 27 months. By 31 months, all
untreated rats were dead. However, 28% of treated rats were
alive at 31 months and the last animal died at 33 months
(Figure 8C). Growth factor treatment increased life expect-
ancy at 27 months by 44%, from 57 to 82 days.
Discussion
Data in the present study indicate that CPC aging conditions
myocardial aging and heart failure. Chronological age leads
to telomeric shortening in CPCs, which generate a progeny
that rapidly acquires the senescent phenotype. Daughter cells
inherit the shortened telomeres of maternal CPCs and, after a
few rounds of division, express the senescence-associated
protein p16INK4a. The pool of old cardiomyocytes progres-
sively increases, and ventricular function is impaired. These
observations in rats are consistent with findings in humans
experiencing aging myopathy.5,20 Progenitor cell aging af-
Figure 7. Cardiac anatomy and function. A, BrdUrd-positive
myocytes. *P0.05 vs 16 to 17 months, **P0.05 vs 21 to 22
months, †P0.05 vs untreated animals. B, p16INK4a-positive
myocytes. *P0.05 vs untreated hearts at 28 to 29 months. C,
LV hemodynamics at baseline (white bars) and 45 days later in
untreated (orange bars) and treated (blue bars) rats. *P0.05 vs
baseline, †P0.05 vs untreated animals.
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fects the function of the brain, pancreas, and bone marrow,6
which, together with current results in the heart, point to stem
cell dysfunction as a critical determinant of organ and
organism aging. However, telomerase-competent CPCs with
long telomeres are present in regions of storage in the atria
and apex, and following activation by growth factors, migrate
to areas of damage, where they create a population of young
myocytes, reversing, to some extent, the aging myopathy
structurally and functionally. The senescent heart phenotype
is partially corrected and the improvement in cardiac perfor-
mance results in prolongation of maximum lifespan.
The loss of CPC function with aging is mediated partly by an
imbalance between factors promoting growth, migration, and
survival and factors enhancing oxidative stress, telomere attri-
tion, and death. Three growth-factor receptor systems appear to
play a role in the development of CPC senescence and myocar-
dial aging: IGF-1/IGF-1R, HGF/c-Met, and RAS. The IGF-1/
IGF-1R induces CPC division, upregulates telomerase activity,
hinders replicative senescence, and preserves the pool of func-
tionally competent CPCs.16,21 The expression of IGF-1R and the
synthesis of IGF-1 are attenuated in aging CPCs, diminishing the
ability of IGF-1 to activate cell growth and interfere with
oxidative damage and telomeric shortening.22 8-OH-dG accu-
mulates in old CPCs, favoring telomere dysfunction, cellular
senescence, and growth arrest. Additionally, the expression and
secretion of HGF in CPCs decreases with age, impacting on their
ability to translocate to areas of damage and promote cardiac
repair.23 Defects in these 2 autocrine–paracrine effector path-
ways may have profound consequences on CPC function and
may account for myocyte death, myocardial scarring, and
depressed performance of the old heart.20
The recognition that a local RAS is present in CPCs and the
formation of Ang II is enhanced in old cells provides evidence in
favor of the role of this octapeptide in CPC senescence and
death. Ang II may contribute to the age-dependent accumulation
of oxidative damage in the heart.24 Inhibition of Ang II function
positively interferes with heart failure and prolongs life in
humans.18 Ang II generates reactive oxygen species, and the
most prominent form of DNA damage induced by free radicals
is 8-OH-dG. In the presence of Ang II, 8-OH-dG increases more
in old than in young CPCs. 8-OH-dG accumulates at the GGG
triplets of telomeres, resulting in telomeric shortening and
uncapping,19 and loss of telomere integrity is the major deter-
minant of cellular senescence and death. Conversely, IGF-1
interferes with reactive oxygen species generation,24 decreases
oxidative stress with age,16 and can repair DNA damage by
homologous recombination.25
The recognition that IGF-1 and HGF modify the effects of
aging on CPC behavior, myocardial composition, ventricular
performance, and maximum lifespan points to IGF-1 and HGF
as potential therapeutic targets of the aging myopathy. Although
it is impossible to discriminate the contribution of each growth
factor to the reversal of myocardial aging in the rat model,
cardiac-restricted overexpression of IGF-1 delays the aging
myopathy and the manifestations of heart failure in transgenic
mice.16 These findings are at variance with the notion that IGF-1
promotes premature aging in fruit flies and nematodes.26 In these
lower organisms, attenuation of insulin/IGF-1 signaling pro-
longs lifespan. However, with adulthood, Caenorhabditis el-
egans and Drosophila lose the regenerative capacity of somatic
tissues, which makes comparisons with mammals hardly feasi-
ble.27 Dying cells cannot be replaced, and this results in a rapid
and progressive decline in organ function. Conversely, cell
turnover by activation and commitment of resident progenitor
cells remains active in mammals throughout life and IGF-1
Figure 8. Cardiac function and mortality. A, Anatomy and hemodynamics of untreated hearts at 16 to 17 months and treated hearts at
28 to 29 months. Triangles indicate individual values. B, Echocardiography at baseline at 27 months and 45 days later in the absence
and presence of treatment. *P0.05 vs the same hearts at 27 months. C, Mortality in untreated and treated animals at 27 months.
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potentiates regeneration in susceptible cells. The impact of
IGF-1 on terminally differentiated cells is complex and only
partially understood. The growth-promoting effects of IGF-1
may be repressed, and metabolic insulin signals may predomi-
nate,28 enhancing oxidative stress and apoptosis.
The modest increase in lifespan of mice heterozygous for the
deletion of IGF-1R is restricted to the female cohort, and the lack
of evidence in males remains unexplained.29 Animal models
with deficiencies in IGF-1 are complicated by the presence of
hypopituitarism, which results in multiple developmental abnor-
malities.30 These confounding factors make the dwarf mice
inappropriate for the assessment of the role of IGF-1 in biolog-
ical aging and lifespan.30 In fact, women live several years more
than men, have a reduced incidence of heart failure, and have a
better prognosis in the presence of heart failure.18 The female
heart is more resistant to aging than the male heart and has an
enhanced expression and nuclear localization of Akt,31 powerful
survival factor and distal effector of IGF-1. Increased levels of
IGF-1 characteristically decrease the incidence of heart failure
and mortality in the elderly population.32 Hormone-replacement
therapy with restoration of IGF-1 levels has significant health
benefits.30 As suggested by the current results, the effects of
IGF-1 on the human heart may involve the CPC compartment
potentiating their ability to divide and differentiate. Translation
of results in simple postmitotic organisms to mammals in which
the life and death of somatic organs is regulated by a stem cell
compartment is open to question.
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Supplemental Data 
Supplemental Materials and Methods 
Animals 
 Male Fischer 344 rats were employed because they develop spontaneously heart failure 
as a function of age.1-3 At comparables age intervals, ventricular decompensation and 
structural abnormalities are attenuated in female rats.4,5 Importantly, a similar behavior 
has been found in humans.6 Additionally, aging effects characterized by myocyte loss, 
myocardial scarring, increased wall stress and impaired myocyte mechanics become 
apparent in male Fischer 344 rats as early as at 12 months of age.1-3,7  
 Under ketamine (100 mg/kg b.w., i.p.) and acepromazine (1 mg/kg b.w., i.p.) 
anesthesia and mechanical ventilation, rats at 15, 20 and 27 months of age were injected 
in the atrioventricular-groove and apex with a retrovirus encoding EGFP. A retrovirus 
was preferred to a lentivirus to infect only cycling cells. By this approach, it was possible 
to prevent the activation of the cell cycle in post-mitotic myocytes. Two days later, HGF 
and IGF-1 (GFs) were delivered intramyocardially. Three injections each were made 
from the atria and apex to the mid-region of the left ventricle (LV). The concentration of 
HGF was increased progressively towards the LV mid-region while the amount of IGF-1 
was maintained constant (supplemental Figure XIII). Control animals of the same age 
were injected with the EGFP-retrovirus and then with vehicle. BrdU was given in the 
drinking water (1 mg/ml) throughout the experiments to label newly formed cells. 
Animals were studied 45 days later.  
Ventricular Function and Anatomy 
Before sacrifice, hemodynamic parameters were obtained in rats non-injected, injected 
with vehicle (untreated) or with GFs (treated). Animals were anesthetized with chloral 
hydrate (300 mg/kg b.w., i.p.), and the right carotid artery was cannulated with a microtip 
pressure transducer (SPR-612, Millar Instruments) connected to an A/D converter (iWorx 
214) and a computer system. The catheter was advanced into the LV chamber for the 
evaluation of LV end-diastolic pressure (LVEDP), systolic pressure (LVSP), developed 
pressure (LVDP) and + and − dP/dt in the closed-chest preparation.1-3,8-10 Wall thickness 
measurements in combination with the radius of the LV chamber (see below) and 
LVEDP were employed to compute diastolic wall stress.  
Following the collection of hemodynamic measurements, the abdominal aorta was 
cannulated with a polyethylene catheter filled with phosphate buffer (0.2 mol/L, pH 7.4) 
and heparin (100 IU/ml). In rapid succession, the heart was arrested in diastole by 
injection of cadmium chloride (100 mmol/L) through the aortic catheter and perfusion 
with phosphate buffer was conducted for ~3 minutes. The thorax was opened and the 
right atrium was cut to allow drainage of blood and perfusate. The heart was then fixed 
by perfusion with 10% phosphate-buffered formalin. Perfusion pressure was adjusted to 
mean arterial pressure. Throughout the procedure, the LV chamber was filled with 
fixative from a pressure reservoir set at a height equivalent to the in vivo measured end-
diastolic pressure.1-3,8-10 After fixation, the heart was dissected and the weights of the 
right ventricle and LV inclusive of the interventricular septum were recorded. The major 
longitudinal axis from the base to the apex of the heart was determined and the LV was 
serially sectioned into five rings perpendicular to this axis. The minimal and maximal 
cavitary diameters and wall thickness at the mid-region of the ventricle were obtained 
and, together with the longitudinal axis, were utilized to compute LV chamber 
volume.11,12 Magnitude of sampling is listed in supplemental Table I. 
Echocardiography 
Echocardiograms were recorded in rats at 27 months before treatment with GFs and 45 
days later after the injection of GFs at 28-29 months. A group of rats injected with 
vehicle was similarly studied. Rats were anesthetized with ketamine (100 mg/kg b.w., 
i.p.), and echocardiographic parameters were collected utilizing an Acuson Sequoia 256c 
equipped with a 13-MHz linear transducer.11,12 The anterior chest was shaved, and rats 
were placed in the left lateral decubitus position. A rectal temperature probe was placed, 
and the body temperature was carefully maintained between 37.0°C and 37.5°C with a 
heating pad throughout the study. The parasternal long-axis, parasternal short-axis, and 
 2
apical four-chamber views were used to obtain 2D, M-mode. Systolic and diastolic 
anatomic parameters were obtained from M-mode tracings at the midpapillary level. 
Ejection fraction (EF) was calculated by the area-length method.11,12  
CPC Number 
This analysis was restricted to c-kit-positive-CPCs in the atria, base-mid-region and apex 
of the LV in rats at 4, 12, 20 and 28 months of age. CPCs were identified by employing 
an antibody against c-kit (R&D Systems). Cell phenotype was defined by 
immunocytochemistry. CPCs were tested for markers of cardiac, skeletal muscle, neural 
and hematopoietic cell lineages to detect Linneg-CPCs.9,10,12 To recognize myocyte 
progenitors and precursors the presence of c-kit together with transcription factors and 
cytoplasmic proteins specific of myocytes was determined. A complete list of antibodies 
used is shown in supplemental Table II.  
Morphometric measurements of CPCs, myocyte progenitors and myocyte 
precursors were obtained by counting at confocal microscopy the number of CPCs or the 
two other cell categories per unit area, N(cpc)A, of LV and atrial myocardium. 
Additionally, the number of CPCs per unit volume of myocardium, N(cpc)V, and the 
average diameter of CPCs, D(cpc), were obtained utilizing the Schwartz-Saltykov 
methodology.13-15 An identical approach was followed for the measurements of myocyte 
progenitors and precursors. Additionally, the number of CPCs that reached replicative 
senescence and irreversible growth arrest16-18 was evaluated by the expression of the 
senescence-associated protein p16INK4a. Also, the fraction of CPCs undergoing 
apoptosis12,14,19 was evaluated by the hairpin 1 to establish the number of functionally-
competent CPCs14,20 in the various anatomical areas of the heart with aging. An identical 
approach was followed to analyze aging effects on the number of CPCs which expressed 
IGF-1 and IGF-1R, HGF and c-Met, and Ang II and AT1 receptors.  
Long-Term BrdU-Retaining Assay 
Rats at 4 and 27 months were divided in two groups each. In the first case, rats at 4 and 
27 months were exposed to BrdU in the drinking water for 7 days and subsequently were 
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sacrificed and studied. In the second case, rats at 4 and 27 months were exposed to BrdU 
in the drinking water for 7 days and studied after a chasing period of 12 weeks, at 7 and 
30 months, respectively. Nearly 70% of the old animals died during the chase-period. 
This reflected the anticipated death rate of male Fischer 344 rats at this age. 
Unfortunately, death occurred mostly during the night and the organs deteriorated rapidly 
after death. This limitation made the identification of the cause of death essentially 
impossible. BrdU-bright and BrdU-dim c-kit-positive-CPCs were counted at both time 
points in both young and old rats. Levels of fluorescence >4,000 and <2,000 units (pixel 
x average intensity) were considered representative of bright and dim cells, 
respectively.15 CPCs with intermediate levels of fluorescence, >2,000 but <4,000, were 
excluded from the analysis. 
These criteria were introduced to score the long-term label-retaining CPCs.15 The 
autofluorescence of the section, together with the signal generated by the irrelevant 
antibody used as a negative control for BrdU staining, was <60 units. Levels of labeling 
>200 units were included. BrdU-negative-CPCs were also counted. An identical approach 
was used to evaluate the fraction of myocyte nuclei labeled by bright and dim BrdU at 7 
days and after 12 weeks of chasing. However, myocyte nuclei with intermediate 
fluorescence intensity (>2,000 and <4,000) were included in the analysis to obtain a 
complete evaluation of the generated myocyte progeny over a period of 12 weeks.15 The 
myocyte mitotic index15,20 was also measured by the expression of phospho-H3 in young 
and old hearts to have a quantitative estimate of the actual population of amplifying 
myocytes in the LV myocardium.10,21   
Isolation and Growth Properties of CPCs 
The heart was dissected, the aorta was removed and the LV myocardium was cut into 
small pieces and incubated in a collagenase solution.9,12 The fraction of small cells was 
enriched by filtration and centrifugation and c-kit-positive-cells were sorted for c-kit with 
rabbit anti-c-kit (Santa Cruz Biotechnology) and magnetic immunobeads (Miltenyi). Cell 
phenotype was defined by immunocytochemistry. Therefore, the separated c-kit-positive-
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cells were fixed in 4% paraformaldehyde for 15 minutes at room temperature and tested 
for multiple markers (supplemental Table II) to detect Linneg-CPCs.9,12,15,20 Committed 
cells expressed the stem cell antigens c-kit, MDR1 or Sca-1 alone or in combination 
together with transcription factors and cytoplasmic proteins of cardiac cells. The growth 
of CPCs was determined by BrdU labeling and population doubling time. Cells were 
labeled with BrdU (1 µg/ml, Roche) for 5 days and BrdU incorporation was determined 
by immunostaining with monoclonal antibody (Roche). For studies of growth kinetics, 
the number of cells per unit area was counted daily and the data were plotted on a semi-
logarithmic scale. Population doubling time was calculated by linear regression analysis. 
Immunocytochemistry 
Formalin-fixed tissue sections, 4 µm in thickness, were employed for these studies. When 
possible, antibodies were directly labeled with fluorochromes (Molecular Probes) or 
quantum dots (Quantum Dot Corporation) to avoid cross-reactivity and autofluorescence 
(supplemental Table II).22,23  
Telomerase Activity and Telomere Length 
Expanded (passage P7-P8) c-kit-positive-CPCs from hearts at 3 and 27 months were 
homogenized in CHAPS buffer and centrifuged at 4°C. Untreated and RNase-treated cell 
extracts were incubated with [γ-32P]ATP-end-labeled telomerase substrate (TS 
oligonucleotide: 5'-AATCCGTCGA-GCAGAGTT-3'), Taq polymerase and anchored 
reverse primer (5'-GCGCGC-[CTAACC]3CTAACC-5') for 45 min. Samples were 
exposed to 28 amplification cycles.20,24,25 PCR products were separated on 12% 
polyacrylamide gel. Telomerase-induced reaction generated a 6-bp ladder. The optical 
density (OD) of the bands was normalized for PCR efficiency.  
Telomere length was evaluated in cytospins of freshly isolated c-kit-positive-cells 
from hearts at 3 and 27 months by quantitative fluorescence in situ hybridization (Q-
FISH) and confocal microscopy.20,26,27 Similarly, telomere length was evaluated in small 
developing myocytes in tissue sections of young and old hearts. A fluorescein 
isothiocyanate-peptide nucleic acid (FITC-PNA) probe was used. The fluorescent signals 
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measured in lymphoma cells with short (L5178Y-S, 7 kbp) and long (L5178Y-R, 48 kbp) 
telomeres (kindly provided by Dr. M.A. Blasco, Spanish National Cancer Centre, 
Madrid) were utilized to compute absolute telomere length. 
CPC Proliferation and Death 
C-kit-positive-CPCs from hearts at 3 and 27 months at P7-P8 were cultured in SFM and 
stimulated with IGF-1 (150 ng/mL), HGF (200 ng/mL), IGF-1 and HGF together (IGF-1-
HGF) or Ang II (10-9mol/L) for 24 hours. BrdU was added to the medium at 8 hour 
intervals. Cells were fixed and BrdU incorporation was measured as previously 
described.9,10,12 In a similar manner, CPCs were stimulated with Ang II (10-9mol/L) alone 
or in the presence of IGF-1 (150 ng/mL), HGF (200 ng/mL) and IGF-1-HGF for 24 
hours. Cells were fixed and apoptosis was determined by the TdT assay.3,14 The effect of 
Ang II (10-9M) for 24 hours on the extent of oxidative stress in CPCs was measured by 
the presence of 8-OH-dG.14 The intensity of the 8-OH-dG signal was measured with an 
ImagePro software19,25 and normalized for the PI fluorescence.  
ELISA 
Expanded c-kit-positive-CPCs from hearts at 3 and 27 months (P5-P6) were cultured in 
SFM and exposed to IGF-1 (150 ng/mL), HGF (200 ng/mL) or Ang II (10-11mol/L) for a 
period of 24 hours. Media containing GFs were removed and cells were washed twice 
and fresh SFM was added. The SFM contained antibodies against IGF-1R (Abcam) and 
c-Met (R&D Systems) or the AT1 receptor antagonist telmisartan (10-7mol/L; Sigma) and 
the AT2 receptor blocker PD123319 (10-7mol/L, Sigma). The blockers were employed to 
avoid ligand binding. Media were collected after 3 and 9 hours for IGF-1, HGF and Ang 
II. GF quantities were determined by ELISA (IGF-1, R&D Systems; HGF, B-Bridge 
International; Ang II, Peninsula Laboratories) and normalized by the total quantity of 
CPC proteins and β-actin (Sigma) expression measured by Western blotting.  
Real-Time RT-PCR 
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Total RNA was extracted from c-kit-positive-CPCs obtained from hearts at 3, 12, 16 and 
24 months with a commercial RNA isolation kit using Trizol (TRI REAGENT, Sigma) as 
described previously in detail.28 cDNA was obtained from 500 ng total RNA in a 20 µl 
reaction containing first strand buffer, 0.4 mM each of dTTP, dATP, dGTP and dCTP 
together with 200U of Superscript III (Invitrogen), 10U of RNase inhibitor (RNasin Plus, 
Promega) and 500 ng of random hexamer (Promega). This mixture was incubated at 42ºC 
for 2 hours. Subsequently, real-time RT-PCR was performed with primers (supplemental 
Table III) designed using the Primer Express v2.0 analysis software (Applied 
Biosystems). The LightCycler PCR system (Roche Diagnostics) was employed for real-
time RT-PCR that was done in duplicates. In each case, 5 ng cDNA were used with the 
exception of renin that required 15 ng. cDNA was combined with SYBR Green master 
mix (LightCycler Fast Start DNA Master SYBR Green I, Roche) and cycling conditions 
were as follows: 95°C for 10 min followed by 45 cycles of amplification (95°C 
denaturation for 10 sec, annealing for 5 sec and 72°C extension for 20 sec). The melting 
curve was then obtained. The annealing temperature used for each primer set is listed in 
supplemental Table III. To avoid the influence of genomic contamination, forward and 
reverse primers for each gene were located in different exons. Reactions containing 
cDNA generated without reverse transcriptase and reactions with primers alone were also 
included. PCR efficiency was evaluated using a standard curve of four serial dilution 
points. Quantified values were normalized against the input determined by the 
housekeeping gene β-actin.  
Real-time PCR products were run on 1.8% agarose/1x TBE gel. Amplified 
fragments were cut out and DNA was extracted using QIAquick Gel Extraction kit 
(Qiagen). DNA was eluted in 30 µl of 10 mmol/L Tris buffer (pH 8.5), and amplified by 
Platinum Blue PCR Supermix (Invitrogen) in the presence of 260 nmol/L of the forward 
and reverse primers utilized for real-time PCR. PCR reaction was carried out in 
Eppendorf Mastercycler. Cycling conditions were as follows: 94°C for 2 min followed by 
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35 cycles of amplification (94°C denaturation for 20 sec, annealing for 30 sec, 72°C 
elongation for 20 sec) with a final incubation at 72°C for 3 min. After purification using 
QIAquick PCR Purification kit (Qiagen), samples were submitted to the DNA 
Sequencing Facility of Cornell University (New York, NY) to obtain the DNA sequence.  
Western Blotting 
Proteins from expanded CPCs (P5-P6) obtained from hearts at 3 and 27 months were 
extracted using M-PER Mammalian Protein Extraction Reagent (Pierce Biotechnology) 
and a cocktail of protease inhibitors (Pierce Biotechnology). Protein concentration was 
measured by Bradford assay (Bio-Rad). Equivalents of 30 µg protein for Aogen and AT1 
receptor were separated on 8% SDS-PAGE. Proteins were then transferred onto 
nitrocellulose membranes, blocked with 5% BSA (AT1 receptor) or 5% dry skim milk 
(Aogen) in Tris-saline buffer with 0.1% Tween20 (TBST) for 1 h at room temperature, 
and exposed to mouse-monoclonal Aogen antibody (Swant) 1/1000 or to mouse-
monoclonal AT1 receptor antibody (Abcam) 1/500 in TBST overnight at 4ºC. HRP-
conjugated IgG were used as secondary antibodies (Pierce Biotechnology). Proteins were 
detected by chemiluminescence (SuperSignal West Femto Maximum Sensitivity 
Substrate, Pierce Biotechnology) and OD was measured.10,19 Loading conditions were 
determined by the expression of β-actin (Sigma). 
Cell Migration 
These studies were restricted to rats at 4 and 27 months. A retrovirus encoding EGFP was 
injected in the atrioventricular-groove to label cycling CPCs (supplemental Figure IV).10 
Two days later, GFs or vehicle were injected and the heart was excised, arrested in 
diastole with 30 mmol/L KCl and placed in a bath mounted on the stage of a two-photon 
microscope (Bio-Rad Radiance 2100MP). The heart was continuously perfused 
retrogradely through the aorta and superfused at 37°C with an oxygenated Tyrode 
solution in the absence or presence of rhodamine-labeled dextran. Dextran has a 
molecular weight of 70,000 and because of this size, dextran does not cross the 
endothelial barrier and remains confined to the coronary vasculature.10,11 EGFP and 
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rhodamine were excited, respectively, at 960 and 840 nm with mode-locked Ti:Sapphire 
femtosecond laser (Tsunami, Spectra-Physics). The corresponding images were acquired 
at emission wavelengths of 515 and 600 nm. By this approach, the translocation of 
EGFP-positive-cells and their localization with respect to the coronary vasculature was 
determined over time.10 Subsequently, hearts were fixed and analyzed by confocal 
microscopy as discussed above.  
Data Analysis and Statistics 
The magnitude of sampling utilized in each in vitro and in vivo determination is listed in 
supplemental Table I. In all cases, results are presented as mean±SD. Significance 
between two comparisons was determined by unpaired and paired Student’s t-test and 
among multiple comparisons by Bonferroni test. Mortality was measured by log-rank 
test. All P values are two-sided and P<0.05 was considered to be significant.  
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Supplemental Figures 
Figure I. CPC senescence and death. A, CPCs/mm3 myocardium. B, Cluster of c-kit-
positive CPCs (green) in the LV at 20 months. Several CPCs express the senescence-
associated protein p16INK4a (white; arrowheads). Myocytes, MHC (red). Propidium iodide 
(PI, blue). Fraction of p16INK4a-positive-CPCs (lower panel). C, Percentage (upper panel) 
and number/mm3 myocardium (lower panel) of apoptotic CPCs. D, Functionally-
competent CPCs/mm3 myocardium (lower panel). E, Myocyte progenitors and 
precursors. *P<0.05 versus 4 months (4m); **P<0.05 versus 12 months (12m); †P<0.05 
versus 20 months (20m).  
Figure II. CPC and myocyte formation. A, Old LV myocardium containing BrdU 
(yellow) bright- (arrows), and dim- (arrowhead) myocytes (α-SA, red) at 7 days. Several 
non-myocyte nuclei are also labeled by BrdU. Negative control (lower panel): LV 
myocardium from a rat at 28 months of age not exposed to BrdU. B, Metaphase 
chromosomes (upper panels: blue, PI; arrows) positive for phospho-H3 (lower panels: 
green) are apparent in small dividing cardiomyocytes (α-SA, red) in LV myocardium of 
young (left panels) and old (right panels) hearts.  
Figure III. Telomere length and replicating myocytes. Young (A) and old (B) LV 
myocardium contains small cycling (Ki67, yellow; arrows) myocytes with long (A) and 
short (B) telomeres. 
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Figure IV. Growth factor receptor systems in CPCs. Freshly isolated CPCs from young 
(A, B, D, E) and old (C, F) hearts express IGF-1R (A, magenta), c-Met (B, yellow) and 
AT1 receptors (C, white) on the membrane and IGF-1 (D, magenta), HGF (E, yellow) 
and Ang II (F, white) in the cytoplasm. 
Figure V. Nucleotide sequences. Sequences of the real-time RT-PCR products were 
established in sense and antisense direction.   
Figure VI. Growth factor treatment. A, Schematically, clusters of CPCs are stored in the 
atria. This anatomical area was injected with EGFP-retrovirus to infect cycling CPCs. 
Two days after infection, increasing concentrations of HGF alone or together with IGF-1 
were delivered intramyocardially from the atria to the LV mid-region to create a 
chemotactic gradient promoting the migration of CPCs-ECCs. B, Section of atrial 
myocardium containing several CPCs (c-kit, white) some of which were infected by the 
EGFP-retrovirus (green; arrows). Myocytes (MHC, red).  
Figure VII. Migration of EGFP-positive-cells. A through E, Two days after the injection 
of the retrovirus, growth factors were administrated and the migration of EGFP-positive-
cells was examined ex vivo in an oxygenated Tyrode solution preparation by two-photon 
microscopy. These images correspond to cell locomotion 10 hours after the 
administration of growth factors in a Fischer 344 rat at 4 months of age. These five 
panels, panel C is shown twice, illustrate the same field examined at intervals of 20 
minutes each. Green fluorescence reflects EGFP-labeled-cells in vivo. Arrowheads of 
various colors point to cells moving in the direction of the large open arrows over a 
period of 80 minutes. The white circle shows cells that appeared in the field and then 
disappeared. The white small square in panel E shows two cells that began to appear in 
panel D.  
Figure VIII. Identity of the migrated EGFP-positive-cells. Panel E in supplemental 
Figure VII is illustrated again here (A). The square defines the EGFP positive cells 
detected in the living tissue by two-photon microscopy and after fixation and staining of 
the same LV region by confocal microscopy, panel B. Green fluorescence in both panels 
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identifies the same cells (A and B). EGFP-positive-cells express c-kit (C, green), MDR1 
(D, yellow), GATA-4 (C, white) and c-Met (E, red). For example, 3 EGFP-positive-cells 
are Ki67-positive (D, magenta; asterisks) and express c-kit, MDR1 and c-Met 
(arrowheads) and 1 EGFP-positive-cell expresses all four proteins (arrow). Myocytes 
(MHC, red). Nuclei (PI, blue).  
Figure IX. Migration of EGFP-positive-cells. A through E, These images correspond to 
cell locomotion 10 hours after the administration of growth factors in a Fischer 344 rat at 
27 months of age. These five panels, panel C is shown twice, illustrate the same field 
examined at intervals of 15 minutes each. Green fluorescence reflects EGFP-labeled-cells 
in vivo. Arrowheads of various colors point to cells moving in the direction of the large 
open arrows over a period of 60 minutes. The red circle shows a cell that was in the field 
and then disappeared. The yellow oval surrounds cells that moved within the field 
throughout the period of observation. 
Figure X.  Identity of the migrated EGFP-positive-cells. Panel E in supplemental Figure 
IX is illustrated again here at higher magnification (A). A, B, Squares and rectangles 
define the EGFP positive cells detected in the living tissue by two-photon microscopy 
(A) and after fixation and staining of the same LV region by confocal microscopy (B). 
Green fluorescence in both panels identifies the same cells (A and B). EGFP-positive-
cells express c-kit (C, green), Sca-1 (D, yellow), GATA-4 (C, white) and c-Met (E, red). 
For example, 7 EGFP-positive-cells express c-kit, Sca-1 and c-Met (arrowheads) and 3 
EGFP-positive-cell express all four proteins (arrows). Myocytes (MHC, red). Nuclei (PI, 
blue).  
Figure XI. Pattern of migration of CPCs. These images were obtained in a Fischer 344 
rat at 4 months of age. The coronary circulation was perfused with an oxygenated Tyrode 
solution containing rhodamine-labeled dextran and the growth factors were administrated 
at the time of observation. The first image was obtained within 15 minutes, which is the 
time required for the adjustment of the microscope on the epicardial surface of the heart. 
A through E, These five panels, panel C is shown twice, illustrate the same field 
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examined at intervals of 20 minutes each. Red fluorescence corresponds to the 
distribution of the coronary vasculature and green fluorescence reflects EGFP-labeled 
cells in vivo. Arrowheads of various colors point to EGFP-positive cells moving in the 
direction of the large open arrows over a period of 80 minutes. In all panels, EGFP 
moving cells were outside of the coronary vessels, suggesting that the coronary 
circulation was not implicated in the migration of EGFP-positive cells (color arrowheads) 
within the myocardium. F, Migrating EGFP-positive cells were located within tunnels 
defined by interstitial fibronectin (yellow). Large arrows point to the direction of 
migration of the EGFP-positive cells.  
Figure XII. Cell migration and cardiac aging. A, Properties of migrating EGFP-positive-
cells in young (4m) and old (27m) hearts with growth factors. *P<0.05 versus 4 months. 
Telomere length (B and C; magenta) in migrating (B) and non-migrating (C) CPCs. 
Migrating CPCs are p16INK4a-negative (D). Non-migrating CPCs are mostly p16INK4a-
positive (E). 
Figure XIII. Growth factor treatment. Schematically, clusters of CPCs are stored in the 
atria and apex. These anatomical areas were injected with an EGFP-retrovirus to infect 
cycling CPCs and ECCs. Two days after infection, increasing concentrations of HGF 
together with IGF-1 were delivered intramyocardially from the atria and apex to the LV 
mid-region. The objective was to create a chemotactic gradient between stored CPCs and 
the damaged myocardium to promote translocation of functionally-competent primitive 
cells to the areas of tissue injury. Control animals were injected with vehicle. Treated and 
untreated animals were examined 45 days later. 
Figure XIV. Myocyte and coronary vessel regeneration. A, Newly formed EGFP-
positive-cardiomyocytes (left panel: EGFP, green; right panel: MHC, red; arrows). B and 
C, Newly formed EGFP-positive capillaries (B, upper panel: EGFP, green; central panel: 
vWF, white; lower panel: merge) and arterioles (C, upper panel: EGFP, green; central 
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panel: α-SMA, red; lower panel: merge). Treated hearts at 16-17m (A), 21-22m (B) and 
28-29m (C). D, *P<0.05 versus 16-17 and 21-22 months. 
Figure XV. Vessel regeneration. BrdU-positive arterioles and capillaries. *P<0.05 versus 
16-17 months. **P<0.05 versus 21-22 months and †P<0.05 versus untreated animals. 
Figure XVI. Cardiac anatomy. LV anatomy at baseline (white bars) and 45 days later in 
untreated (orange bars) and treated (blue bars) rats. *P<0.05 versus baseline and †P<0.05 
versus untreated-animals.  
Figure XVII. Echocardiography. M-mode echocardiography of rats at 27 months and 45 
days later in the absence (A) and presence (B) of growth factor treatment. The 
improvement in cardiac performance with treatment is apparent. 
Supplemental Movies 
Movie I, II. Echocardiographic recordings. Two examples of the positive changes in 
function with growth factor treatment.  
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Supplemental TABLE I: Magnitude of Sampling 
 
 
Parameter                                                         n                        Aggregate                        Mean±SD 
 
Number of CPCs, Myocyte Progenitors and Precursors 
4 months 
 Atria  6 215(1) 36±11         
 Base-Mid  6 863(1)  144±20         
 Apex  6 392(1) 65±16         
12 months 
 Atria  6 229(1) 38±6         
 Base-Mid  6 761(1)  127±18         
 Apex  6 391(1) 65±12         
20 months 
 Atria  6 201(1) 34±7         
 Base-Mid  6 913(1)  152±19         
 Apex  6 446(1) 74±15         
28 months 
 Atria  6 233(1) 39±5         
 Base-Mid  6 765(1)  128±16         
 Apex  6 321(1) 54±13         
     
Fraction of p16INK4a-Positive CPCs 
4 months 
 Atria  6 643(1) 107±34         
 Base-Mid  6  2580(1) 430±57         
 Apex  6  1177(1) 196±47         
12 months 
 Atria  6 458(1)    76±12         
 Base-Mid  6  1523(1) 254±37         
 Apex  6 782(1) 130±24         
20 months 
 Atria  6 402(1) 67±14         
 Base-Mid  6  1822(1)  304±38         
 Apex  6 888(1)  148±30         
28 months 
 Atria  5 384(1) 77±9         
 Base-Mid  5  1292(1)  258±35         
 Apex  5 545(1)  109±29        
 
Fraction of Apoptotic CPCs 
4 months 
 Atria  6 926(1) 154±62         
 Base-Mid  6  4606(1)   768±203         
 Apex  6  1089(1) 182±50         
12 months 
 Atria  6 615(1)  103±11         
 Base-Mid  6  2843(1)  474±48         
 Apex  6 834(1)  139±45         
20 months 
 Atria  6 371(1) 62±16         
 Base-Mid  6  1185(1)  198±37         
 Apex  6 412(1)   69±14         
28 months 
 Atria  5 243(1) 49±10         
 Base-Mid  5 699(1)  140±34         
 Apex  5 275(1) 55±12        
     
Pulse-Chase BrdU Labeling 
 4 months CPC pulse 5 1761(2)   352±64           
   4 months CPC chase 5 2887(2)   577±216           
 27 months CPC pulse 5 2726(2)   545±121           
 19
   27 months CPC chase 5 2425(2)   485±110           
 4 months Myocytes pulse 5 8967(2) 1793±613           
   4 months Myocytes chase 5 3541(2)   708±213           
 27 months Myocytes pulse 5 1831(2)   366±74           
   27 months Myocytes chase 5 1187(2)  237±29           
 
Mitotic Index 
Myocardial sections 
 4 months  6 781(2)  130±31         
 27 months  6 794(2)    132±27         
Isolated myocytes 
 4 months  5  92140(2)  18428±4258         
 27 months  7  55490(2)  7927±4517         
 
Telomere Length 
 3 months 6 1404(2)  234±183           
   27 months 6 1298(2)  216±134           
 
BrdU Labeling in vitro 
3 months 
 Control  5  3700(2) 740±267        
 IGF-1  5  1562(2) 312±163         
 HGF 5  2273(2) 455±177         
       IGF-1 + HGF 5  1718(2) 344±226    
 AngII 5  4408(2) 882±211              
27 months 
 Control  5  4326(2) 865±140        
 IGF-1  5  2807(2) 561±193         
 HGF 5  4010(2) 802±247         
       IGF-1 + HGF 5  2831(2) 566±136    
 AngII 5  4845(2) 969±89              
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Apoptosis Labeling in vitro 
3 months 
 Control  5  4790(3) 958±180        
 AngII  5  2162(3) 432±129         
 AngII + IGF-1 5  5042(3)   1008±89         
       AngII + HGF 5  2270(3) 454±123    
 AngII + IGF-1 + HGF 5  5025(3)   1005±41              
27 months 
 Control  5  5154(3) 1031±27        
 AngII  5  4812(3) 962±151         
 AngII + IGF-1 5  5078(3)   1016±14         
       AngII + HGF 5  4835(3) 967±163    
 AngII + IGF-1 + HGF 5  5127(3)   1025±7              
 
ELISA of IGF-1, HGF and Ang II 
  3 months        5       N/A            N/A 
   27 months        5       N/A            N/A 
 
Real-Time RT-PCR         
  3 months        5       N/A            N/A 
   12 months        6       N/A            N/A 
  16 months        6       N/A            N/A 
   24 months        5       N/A            N/A 
 
Western Blotting 
  3 months        5       N/A            N/A 
   27 months        5       N/A            N/A 
 
Telomerase Activity 
   3 months        5       N/A            N/A 
   27 months        5       N/A            N/A 
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8-OHdG in vitro 
 3 months, SFM 5 2051(3)   410±71           
   3 months, AngII 5 1460(3)   292±56           
 27 months, SFM 5 1444(3)   289±90           
   27 months, AngII 5 1108(3)   222±43           
 
Growth Factors and their Receptors 
IGF-1 
 4 months  6  282(3) 47±8        
 12 months  6  337(3)   56±11         
 20 months 6  490(3) 82±10         
       28 months 5  370(3) 74±14         
IGF-1R 
 4 months  6  273(3) 46±6        
 12 months  6  314(3)   52±15         
 20 months 6  385(3) 64±20         
       28 months 5  384(3) 77±18         
HGF 
 4 months  6  294(3) 49±8        
 12 months  6  309(3)   52±8         
 20 months 6  401(3) 67±17         
       28 months 5  317(3) 63±17         
c-Met 
 4 months  6  257(3) 43±8        
 12 months  6  290(3)   48±16         
 20 months 6  383(3) 64±21         
       28 months 5  325(3) 65±31         
AngII 
 4 months  6  472(3) 79±14        
 12 months  6  478(3)   80±16         
 20 months 6  450(3) 75±16         
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       28 months 5  371(3) 74±18         
AT1R 
 4 months  6  449(3) 75±13        
 12 months  6  464(3)   77±18         
 20 months 6  480(3) 80±12         
       28 months 5  369(3) 74±17         
 
Growth Factor Stimulation of Migration 
4 months 
 HGF  4 421(3) 105±18         
 IGF-1  4 343(3)     86±18         
 HGF + IGF-1  4 402(3) 101±15         
27 months 
 HGF  4 328(3)   82±18         
 IGF-1  4 290(3) 73±7         
 HGF + IGF-1  4 315(3) 79±18         
 
BrdU Labeling in GF-treated rats 
16-17 months 
 Untreated 
 Myocytes  5 2639(2) 528±72         
 SMCs  5 1534(2)   307±56         
 ECs  5 1769(2) 354±117         
 Treated 
 Myocytes  5 1967(2) 393±46         
 SMCs  5 1526(2)   305±42         
 ECs  5 1428(2) 286±75         
21-22 months 
 Untreated 
 Myocytes  5 1975(2) 395±80         
 SMCs  5 1308(2)   262±40         
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 ECs  5 1429(2) 286±54         
 Treated 
 Myocytes  5 1251(2) 250±43         
 SMCs  5 1441(2)   288±66         
 ECs  5 1580(2) 316±57         
28-29 months 
 Untreated 
 Myocytes  6 2293(2) 382±37         
 SMCs  6 1601(2)   267±40         
 ECs  6 1940(2) 323±83         
 Treated 
 Myocytes  6 1042(2) 174±37         
 SMCs  6 1754(2)   292±27         
 ECs  6 1667(2) 278±25         
 
p16INK4a Labeling in GF-treated Rats 
 Untreated 8  1726(2) 216±15           
   Treated 12  3115(2) 260±25           
 
Anatomy 
 15 months 6 N/A   N/A           
   16-17 months untreated 10 N/A N/A           
   16-17 months treated 9 N/A N/A           
   20 months 9 N/A N/A           
   21-22 months untreated 10 N/A N/A           
   21-22 months treated 9 N/A N/A           
   27 months 8 N/A N/A           
   28-29 months untreated 10 N/A N/A           
   28-29 months treated 18 N/A N/A           
 
Hemodynamics 
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 15 months 9 N/A   N/A         
   16-17 months untreated 10 N/A N/A           
   16-17 months treated 6 N/A N/A           
   20 months 8  N/A N/A 
   21-22 months untreated 10 N/A N/A           
   21-22 months treated 9 N/A N/A           
   27 months 7 N/A N/A  
   28-29 months untreated 10 N/A N/A           
   28-29 months treated 12 N/A N/A           
 
Echocardiography 
 Untreated   9 N/A   N/A           
   Treated 14 N/A N/A 
 
Mortality 
 Untreated 32 N/A   N/A           
   Treated 48 N/A N/A 
 
(1) Area of tissue sampled, mm2; (2) Number of nuclei analyzed; (3) Number of counted cells; N/A, 
not applicable. 
 
 
 
 
 
 
 
 
 25
Supplemental Table II: Antibodies and their labeling 
 
Protein  Antibody  Labeling Fluorochrome(s) 
 
Stem cell markers 
   
c-kit goat polyclonal direct and indirect F, T, Cy5, QD655 
MDR-1 mouse monoclonal direct and indirect F, T, Cy5, QD655 
Sca-1 rat monoclonal direct and indirect F, T, Cy5, QD655 
Structural proteins of myocardial cells 
   
α-sarcomeric actin mouse monoclonal direct and indirect F, T, Cy5, QD655 
β-myosin heavy chain mouse monoclonal direct and indirect T, QD655 
von Willebrand factor sheep polyclonal direct and indirect T, Cy5, QD655 
α-smooth muscle actin mouse monoclonal direct and indirect F, T, Cy5, QD655 
Transcription factors of myocardial cells
 
   
MEF2C goat polyclonal direct and indirect T, Cy5, QD655 
GATA-4 mouse monoclonal direct and indirect T, Cy5, QD655 
Nkx2.5 goat polyclonal direct and indirect T, Cy5, QD655 
Growth factors 
   
HGF rabbit polyclonal direct and indirect T, Cy5, QD605 
IGF-1 goat polyclonal direct and indirect T, Cy5, QD605 
AngII rabbit polyclonal  direct and indirect T, Cy5, QD605 
c-Met rabbit polyclonal direct and indirect T, Cy5, QD605 
IGF-1R mouse monoclonal direct and indirect T, Cy5, QD605 
AT1 receptor rabbit polyclonal direct and indirect T, Cy5, QD605 
Other stainings 
   
Ki67 rabbit polyclonal direct and indirect Cy5, QD655 
BrdU mouse monoclonal direct and indirect Cy5, QD655 
Phospho-H3 rabbit polyclonal direct and indirect Cy5, QD655 
p16INK4a mouse monoclonal direct and indirect Cy5, QD655 
8-OH-dG rabbit polyclonal direct and indirect Cy5, QD655 
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EGFP rabbit polyclonal direct and indirect Cy5, QD655 
Telomeres  direct F 
TUNEL TdT/dUTP direct F 
Laminin rabbit polyclonal direct and indirect Cy5, QD655 
 
Direct labeling: Primary antibody conjugated with the fluorochrome. Indirect labeling: species-specific 
secondary antibody conjugated with the fluorochrome. F: fluorescein isothiocyanate, T: tetramethyl 
rhodamine isothiocyanate, Cy5: cyanine 5, QD655: quantum dots with emission at 655 nm, QD605: 
quantum dots with emission at 605 nm. 
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Supplemental TABLE III: Primers and annealing temperatures used in the real-time RT-PCR  
 
Gene Forward primer (5’→ 3’) Reverse primer (5’→ 3’) Annealing T 
(ºC) 
IGF-1 (Igf1) CGAACCTCCAATAAAGATACAC CAACACTCATCCACAATGCC 61 
IGF-1R (Igf1r CGAGCAAGTTCTTCGTTTCGT TGTACTGCCAGCACATGCG 61 
HGF (Hgf) TGCCCTATTTCCCGTTGTG AATGCCATTTACAACTCGCAGTT 61 
c-Met (Met) ACAACAAAACGGGTGCGAAA TCATGAGCTCCCAGAGAAGCA 61 
Renin (Ren1) CCTGGGAGTCAAAGAGAAGAG GTATAGAACTTGCGGATGAAGG 62 
Aogen (Agt) ATCAACAGGTTTGTGCAGGC GTTGTCCACCCAGAACTCATGG 66 
AT1 receptor (Agtr1) GTCCTCTCAGCTCTGCCACATT CACTTGACCTTTACCTGGTGATCA 64 
B-actin (Actb) ACCCTGTGCTGCTCACCGAG CCAGTGGTACGACCAGAGGC Same as 
target gene 
 
 
 


























